RxDoctor Payments Data

Bradley Hammer, MD

Ophthalmology · W Des Moines, IANPI 1467451047

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,100 of the $9,511 with a category attached, or 64.1%. Carl Zeiss Meditec, Inc. accounts for 64.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $6,779 and has fallen 86.0% since, to $950 in 2025. Among ophthalmology clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$9,511in general payments, 2019–2025

Across 113 payments — averaging $84.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec, Inc.$6K
  • AbbVie$1K
  • Bausch & Lomb Americas Inc.$346
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$307
  • Sun Pharmaceutical Industries Inc.$305
  • Amgen$237
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$6,10064%
  • Food & beverage$3,41136%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,511 in reported general payments places this provider in the 90th percentile of 172 ophthalmology providers in Iowa.

See all ophthalmology providers in Iowa

Medicare billing

Part B allowed, 2024
$288,813
Medicare patients
1,674
Services billed
3,071

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost69$43,230
RestasisCyclosporine21$31,977
CombiganBrimonidine Tartrate/Timolol45$17,278
Travoprost67$8,586
IstalolTimolol Maleate14$6,682
Cyclosporine13$4,409
Timolol Maleate108$3,561
ValacyclovirValacyclovir Hcl66$2,392
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat157$2,247
Latanoprost172$1,951
Prednisolone Acetate50$1,692
Ofloxacin46$393
Doxycycline Hyclate28$321
ErythromycinErythromycin Base30$297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$1,007$92,485135 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCIstalol$307$6,68214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 172 ophthalmology providers in Iowa.

Other ophthalmology in W Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →